Route 92 Medical has today announced the issuance of the company’s 80th global patent for its Monopoint operating platform. Route 92 claims this is “the only neurointervention platform” designed to streamline the delivery of large- and super-bore catheters for aspiration at the most common stroke targets.
The company’s newest patent, US Patent No. 11,576,691, relates to its innovative Tenzing delivery catheter for advancing catheter systems within the neurovasculature.
The Tenzing catheter is part of the Monopoint platform, which is designed to enable a single operator to perform even the most complex procedures to treat large vessel occlusions that cause acute ischaemic stroke. This single-platform system is intended for efficient and effective neurovascular intervention with a design that eliminates length challenges and provides a single point of control for enhanced single-operator capability.
“Route 92 Medical is poised to disrupt the neurointerventional market with products that are designed to treat ischaemic strokes by enhancing delivery in challenging anatomy using our unique single-point-of-control approach,” said Tony Chou, the company’s founder and CEO. “Our intellectual property strength, combined with our world-class team, give us a strong position from which we can make a positive difference in the lives of stroke patients and their families.”
As per a company press release, the Route 92 patent portfolio is growing rapidly, with 46 patents issued in 2022 alone—including claims across the company’s Monopoint portfolio, which encompasses its Tenzing and HiPoint catheter devices.